Establishment of

Baltic Biomaterials Centre of Excellence

Latvian Institute of Organic Synthesis (LIOS), Laboratory of Pharmaceutical Pharmacology (LPP)

The core competences of LIOS are medicinal chemistry and innovative drug discovery with outstanding expertise in preclinical drug development. Laboratory of Pharmaceutical Pharmacology (LPP) is specialising in investigation of the molecular action mechanisms and biological activity testing of compounds and materials in collaboration with partners in the pharmaceutical industry. The expertise of LPP includes obtaining proof of concept for novel drug targets, and therapeutic drug target discovery, screening of biological activity and preclinical evaluation of drug candidates. Pharmacological testing includes investigation of biochemical and physiological effects, mechanisms of action, absorption, distribution, biotransformation and excretion. The approaches range from the molecular and cellular through electrophysiology and organ systems to in vivo models and behaviour. In vivo experiments are followed by biochemical assays of circulating signalling molecules in blood samples as well as gene expression and immunohistochemical analysis of obtained tissue samples.

BBCE project´s main objective is to establish a joint Baltic Biomaterials Centre of Excellence for advanced biomaterials development based on the long-term strategic cooperation between AO Research Institute Davos, Switzerland (ARI) and Friedrich-Alexander University of Erlangen-Nuremberg, Germany (FAU) on the one hand and RTU RBIDC, LIOS and RSU on the other hand.



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 763721